Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kingsoft Cloud Holdings Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Kingsoft Cloud Holdings Limited trades at $11.72 (market cap $3.53B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.4× Kingsoft Cloud Holdings Limited's market cap, and Kingsoft Cloud Holdings Limited is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | KC | |
|---|---|---|
Market Cap | $29.60B | $3.53B |
Sector | Health | Technology |
52-Week High | $491.22 | $18.21 |
52-Week Low | $205.48 | $8.58 |
Enterprise Value | $27.56B | $3.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Kingsoft Cloud (KC) trades at $11.67, down 2.42% today, amid a bullish technical signal with strong analyst support. The company shows robust revenue growth, with Q1 2026 sales up 37% year-over-year, but remains unprofitable with a net margin of -9.39%. Recent news highlights AI-driven growth, with AI cloud billing now surpassing half of public cloud revenue, fueling positive sentiment.
KC presents a high-risk, high-reward opportunity. The bullish analyst consensus (70% buy ratings) and AI expansion offer significant upside potential, but persistent losses, high debt, and China regulatory risks pose substantial threats. Profitability improvement is critical for sustaining investor confidence and justifying current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
